SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.
Microsoft Azure customers worldwide can now discover and deploy the Ares® Networks Agent Governance Platform through Microsoft Marketplace, accessing trusted solutions that accelerate innovation...
The collaboration builds the first digital twin of a stellarator fusion power plant and leverages world leading AI, physics, and engineering for the U.S. Department of Energy’s Genesis Mission
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
SACRAMENTO, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- The intersection of artificial intelligence and blockchain technology is entering a critical maturation phase, where speculative narratives are increasingly being replaced by projects that prioritize tangible network infrastructure. Solana Unchained stands at the forefront of this shift, constructing a decentralized environment where native tokens are not merely held for appreciation, but are required to power essential software utilities.
CLARKSVILLE, Tenn., June 5, 2026 /PRNewswire/ -- What leadership skills are most essential for building healthy and effective teams? In a HelloNation article, Expert...
Three new NASBA-approved live webinar courses on Health Savings Accounts are now available from Roy Ramthun, who led the U.S. Treasury's implementation of HSAs...
The Arizona residential treatment center introduces broader awareness of its trauma-informed and salutogenic recovery model through Forward-Facing® Accelerated Recovery
The Arizona residential treatment center introduces broader awareness of its trauma-informed and salutogenic recovery model through Forward-Facing® Accelerated Recovery
Together, IDEMIA Public Security and Nevetal are shaping the next generation of digital journeys across the cruise ecosystem.COURBEVOIE, France, June 4, 2026 /PRNewswire/ --...